Japan PCSK9 Rivalry Builds As Praluent Edges Closer To Market
This article was originally published in PharmAsia News
Executive Summary
Sanofi's Praluent looks set to become the second PCSK9 inhibitor available in Japan following a new recommendation for approval, but can it hold its own against launched rival Repatha? Meanwhile, AstraZeneca’s Brilinta is facing a delay.